BiotechTube

LY3537031 + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Use Disorder

Conditions

Alcohol Use Disorder

Trial Timeline

Oct 16, 2025 → Apr 1, 2028

NCT ID
NCT07219953

About LY3537031 + Placebo

LY3537031 + Placebo is a phase 3 stage product being developed by Eli Lilly for Alcohol Use Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07219953. Target conditions include Alcohol Use Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Alcohol Use Disorder were approved

Approved (11) Terminated (3) Active (7)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅Selincro® 18 mg with continuous psychosocial support: Cohort ALundbeckApproved
✅nalmefeneLundbeckApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT07219953Phase 3Recruiting
NCT07219966Phase 3Recruiting
NCT06606106Phase 1Active
NCT04648865Phase 1Completed

Competing Products

20 competing products in Alcohol Use Disorder

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
Mazdutide + PlaceboEli LillyPhase 2
42
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47